TAKEDA PHARMACEUTICAL CO LTD
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.
A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.
CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TAK (TAKEDA PHARMACEUTICAL CO LTD). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent TAK coverage spans regulation, technology and financial news.
In the last 30 days, TAK insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($640K). The most active reporter was Duprey Lauren Rusckowski, Chief Transformation Officer, with 1 filing.
Positive trial results for zasocitinib suggest a competitive advantage for Takeda's pipeline.
Takeda's participation may be viewed positively for its oncology pipeline.
Takeda's exposure to the GLOBE program is now minimal, diminishing any upside from the initiative.
The ruling may limit Takeda's ability to extend patent protection, likely pressuring the stock.
Approval likely lifts Takeda's share price as investors price in a new blockbuster therapy.
AlphAI scores every news story that mentions TAK with an AI model for sentiment and relevance, and aggregates insider trades from TAKEDA PHARMACEUTICAL CO LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.
2 min readA phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.
3 min readCMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.
4 min readThe UK High Court ruled on Takeda's ADHD drug Elvanse, questioning whether an inactive precursor can qualify for a patent extension. The decision may impact future drug patent strategies, according to legal experts.
1 min readTakeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.
3 min readTakeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.
2 min readTakeda (TSE:4502/NYSE:TAK) will present data on its oncology pipeline at ESMO 2026, including Phase 3 results for arcotatug tavatecan in advanced gastric cancer and findings on TAK-928 for NSCLC. The company is expanding a global Phase 3 study for TAK-928.
2 min readTakeda Pharmaceutical (TAK) announced FDA priority review for zasocitinib, a treatment for moderate-to-severe plaque psoriasis, with a target action date in Q1 2027. The application includes Phase 3 studies showing significant skin clearance compared to placebo. The company also reported positive results from a head-to-head study against deucravacitinib, highlighting potential differentiation. Approval and commercial access will determine revenue potential.
2 min readGlobal investment in longevity biotech reached $18.4bn in 2025, up from $4.7bn in 2024, with $12.1bn invested in 2026, according to Longevity.Technology. The report predicts a $617bn market by 2045, with gerotherapeutic drugs approved by 2035. Big Pharma companies like Eli Lilly, Takeda, and Novo Nordisk are investing in the sector.
3 min readTakeda Pharmaceutical's (TAK) Chief Transformation Officer sold 34,535 shares on 2026-09-14, continuing a year-long insider selling trend. The company's shares trade at $18.54, with a market cap of $59.72 billion. GuruFocus values the stock at $14.16, indicating it is significantly overvalued. Some institutional investors have increased holdings despite insider sales.
2 min read
